Speaking at the launch of the CiplaQCiL initial public offering, Paul Bwiso, CEO USE termed the decison for the pharmaceutical giant to open up to the public as remarkable. CiplaQCiL came to the market at UGX.256.5 offer price per offer share. A price that created a fun fact labelling the IPO as the Country Coded IPO.
To read more on this, view the attachment below. Please read the prospectus.